Halozyme Therapeutics, Inc. (HALO)
70.35
-0.29
(-0.41%)
USD |
NASDAQ |
Feb 24, 16:00
70.29
-0.06
(-0.09%)
After-Hours: 19:38
Halozyme Therapeutics EPS Diluted (Quarterly) : -1.203 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 2.098 |
| Merck & Co., Inc. | 1.191 |
| Skye Bioscience, Inc. | -0.3216 |
| AIM ImmunoTech, Inc. | -1.567 |
| Stryker Corp. | 2.197 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -141.59M |
| Revenue (Quarterly) | 451.77M |
| Total Expenses (Quarterly) | 593.36M |
| Enterprise Value | 10.37B |
| Gross Profit Margin (Quarterly) | 77.39% |
| Profit Margin (Quarterly) | -31.34% |
| Earnings Yield | 3.54% |
| Operating Earnings Yield | 9.46% |
| Normalized Earnings Yield | 6.525 |